In addition, in an NSCLC patient‐derived xenograft with KRAS G12C mutation, ARS‐1620 showed tumor regression, and effectively inhibited the downstream ERK phosphorylation and activated apoptosis.95 This evidence concerns the gene KRAS and neoplasm.